Myeloproliferative neoplasms are rare blood cancers where the bone marrow produces too many blood cells, affecting thousands of people each year. While these conditions develop slowly and are usually not curable, a range of treatments—from medications to advanced therapies—can help control symptoms, prevent complications, and allow many people to live near-normal lifespans.

Understanding Treatment Goals for Myeloproliferative Neoplasms

When someone is diagnosed with a myeloproliferative neoplasm (or MPN for short), the main focus of treatment is to help them live as well as possible while managing this long-term condition. Because MPNs are chronic blood cancers that develop slowly, the treatment approach aims to relieve symptoms, slow down how the disease progresses, and prevent serious complications like blood clots, heart attacks, or strokes.^[1]

The treatment plan your doctor recommends depends on several important factors. These include which type of MPN you have—such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis—as well as what stage your disease is in and your personal risk factors. Your age, overall health, blood cell counts, and whether you have symptoms all play a role in deciding the best approach.^[2]

For people with low-risk MPNs who don’t have symptoms, doctors may suggest a watch-and-wait approach instead of starting treatment right away. This means closely monitoring your condition through regular blood tests and check-ups to see if anything changes. If your risk level increases or symptoms appear, treatment can then begin.^[21]

Medical professionals use treatments that have been approved by health organizations and follow guidelines established by experts in blood cancers. At the same time, researchers are constantly working on new therapies that are being tested in clinical trials. These studies explore innovative ways to control MPNs, reduce complications, and improve quality of life for patients.^[18]

It’s important to understand that in most cases, MPNs cannot be completely cured. However, advances in treatment have transformed these diseases into manageable long-term conditions. Many people with MPNs can expect to live for many years with the right care, and some may even enjoy a near-normal lifespan. The only treatment currently considered curative is a stem cell transplant, which is typically reserved for specific situations, particularly for some people with myelofibrosis or those whose disease has transformed into a more aggressive blood cancer.^[18]

Standard Treatment Approaches for Myeloproliferative Neoplasms

Standard treatments for myeloproliferative neoplasms have been developed over many years and are recommended by medical societies based on extensive experience with these conditions. The specific treatments used depend on which type of MPN you have, as each affects different blood cells in different ways.

Venesection (Phlebotomy) for Polycythemia Vera

For people with polycythemia vera—a condition where the bone marrow makes too many red blood cells—one of the simplest and most common treatments is venesection, also called phlebotomy. This is a straightforward procedure where about a pint of blood is removed from your body, similar to donating blood. Removing blood reduces the number of red blood cells circulating in your bloodstream, which helps prevent your blood from becoming too thick. Thick blood can slow down circulation and increase the risk of dangerous blood clots.^[8]

This procedure is performed regularly, with the frequency depending on how quickly your red blood cell count rises. For some people, it might be needed every few weeks at first, then less often as the condition stabilizes. Venesection is generally very safe and has few side effects, though some people may feel tired or dizzy afterward.

Aspirin for Preventing Blood Clots

Low-dose aspirin is frequently prescribed for people with MPNs, especially polycythemia vera and essential thrombocythemia. Aspirin works by making platelets (the blood cells that help form clots) less sticky, which reduces the risk of dangerous blood clots that can cause heart attacks or strokes. This simple medication, taken daily in low doses, has proven effective in preventing these serious complications.^[21]

Not everyone with an MPN needs aspirin, however. Your doctor will consider your individual risk factors, including your age, medical history, and whether you’ve had blood clots before. Some people may have an increased risk of bleeding rather than clotting, and in those cases, aspirin might not be recommended.

Hydroxyurea for Controlling Blood Cell Production

Hydroxyurea is one of the most commonly used medications for treating MPNs. It’s a type of drug that slows down the rapid production of blood cells in the bone marrow. By doing this, it helps bring elevated blood cell counts back toward normal levels. Hydroxyurea is often prescribed for people with polycythemia vera, essential thrombocythemia, or myelofibrosis who have a higher risk of complications.^[21]

This medication is typically taken as a capsule once daily, and the dose is adjusted based on your blood test results. Your doctor will monitor your blood counts regularly—usually every few weeks initially, then less frequently once your counts stabilize. Hydroxyurea is generally well-tolerated, but it can cause side effects. Common ones include low white blood cell counts (which can increase infection risk), mouth sores, skin changes, and upset stomach. Some people may experience nail changes or thinning hair.

Interferon Therapy

Interferons are substances that occur naturally in the body and help regulate the immune system. Synthetic versions can be used as treatment for MPNs. Interferon therapy works by slowing down the abnormal growth of blood cells in the bone marrow and may help control the genetic mutations that drive MPNs. This treatment is sometimes preferred for younger patients or women who are pregnant or planning to become pregnant, as it may be safer than other options in these situations.^[21]

Interferon is given as an injection under the skin, typically once or twice a week. The treatment duration varies from person to person and may continue for years. Side effects can be significant and may include flu-like symptoms (fever, chills, muscle aches), fatigue, depression, and changes in blood counts. These side effects often improve over time as your body adjusts to the medication. Newer, longer-acting forms of interferon called pegylated interferons are now available and may be better tolerated because they’re given less frequently.

Anagrelide for High Platelet Counts

Anagrelide is a medication specifically designed to lower platelet counts in people with essential thrombocythemia or other MPNs where platelets are elevated. Unlike hydroxyurea, which affects all blood cell types, anagrelide primarily targets platelets. It works by interfering with the maturation of platelet-producing cells in the bone marrow.^[21]

Anagrelide is taken by mouth, usually twice daily. The dose is gradually increased until your platelet count reaches a safe level. Because this medication affects the heart and blood vessels, your doctor will monitor your heart function. Common side effects include headaches, dizziness, fluid retention, palpitations (feeling your heart beating), and digestive upset. These effects are usually mild and often decrease with time.

Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

For people with chronic myeloid leukemia (CML)—a type of MPN characterized by the presence of the BCR-ABL1 gene mutation (also called the Philadelphia chromosome)—specific drugs called tyrosine kinase inhibitors (TKIs) have revolutionized treatment. These medications work by blocking the abnormal protein produced by the mutated gene, which is what drives the cancer cells to grow.^[21]

Common TKIs include imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), and ponatinib (Iclusig). These are taken daily as pills and have transformed CML from a rapidly fatal disease to a manageable chronic condition. Many people with CML who take these medications can achieve near-normal life expectancies. Side effects vary depending on which TKI is used but may include nausea, muscle cramps, fluid retention, skin rashes, and changes in blood counts.

Treatment in Clinical Trials

While standard treatments help many people manage their MPNs effectively, researchers continue to search for better options. Clinical trials are research studies that test new drugs or treatment approaches to see if they are safe and effective. These trials offer hope for improved outcomes and may provide access to cutting-edge therapies before they become widely available.

JAK2 Inhibitors: Targeting the Genetic Root

One of the most important discoveries in MPN research has been identifying specific genetic mutations that cause these diseases. The most common is a mutation in the JAK2 gene, which is found in more than 95% of people with polycythemia vera and about 50-60% of those with essential thrombocythemia or primary myelofibrosis. Other mutations include changes in the CALR (calreticulin) and MPL (thrombopoietin receptor) genes.^[3]

Understanding these mutations led to the development of drugs called JAK inhibitors, which block the abnormal signaling that drives excessive blood cell production. Ruxolitinib was the first JAK2 inhibitor approved for treating MPNs and has shown significant benefits, particularly for people with myelofibrosis. It helps reduce spleen size (the spleen often becomes enlarged in myelofibrosis), improves symptoms like fatigue and night sweats, and enhances quality of life.^[21]

Researchers are now testing newer JAK inhibitors in clinical trials to see if they can provide even better results with fewer side effects. These trials are being conducted at specialized medical centers around the world, including in the United States, Europe, and other regions. Side effects of JAK inhibitors can include low blood counts (anemia, low platelets), increased risk of infections, and in some cases, increased risk of certain cancers. However, many people tolerate these medications well, and the benefits often outweigh the risks.

Phase I, II, and III Trials: Understanding the Process

Clinical trials for new MPN treatments typically progress through three phases. Phase I trials focus primarily on safety—researchers want to determine the appropriate dose and identify potential side effects. These trials usually involve a small number of participants and are the first time a new drug is tested in humans.^[2]

Phase II trials expand the testing to more people and focus on whether the treatment actually works—does it reduce blood cell counts, shrink the spleen, improve symptoms, or slow disease progression? These trials also continue to monitor safety. If a treatment shows promise in Phase II, it moves to Phase III.

Phase III trials are large studies that compare the new treatment directly with the current standard treatment. These trials involve hundreds or even thousands of participants and provide the strongest evidence about whether a new therapy is truly better than existing options. If Phase III results are positive, the drug may be approved by regulatory agencies like the FDA (in the United States) or EMA (in Europe) for widespread use.

Novel Therapeutic Approaches Under Investigation

Beyond JAK inhibitors, researchers are exploring several other innovative approaches for treating MPNs. These include drugs that work through different mechanisms to control the disease or address complications.

Some clinical trials are testing medications that target other molecular pathways involved in MPNs, such as drugs that affect how genes are expressed or that interfere with other signaling proteins in cancer cells. Other studies are evaluating combinations of drugs—for example, using a JAK inhibitor together with another medication—to see if combining treatments produces better results than using either alone.

Scientists are also studying drugs that might reduce the scarring (fibrosis) that develops in the bone marrow of people with myelofibrosis. This scarring disrupts normal blood cell production and is one of the most challenging aspects of advanced MPN. Treatments that could reverse or prevent fibrosis would represent a major advance.

Another area of research involves drugs called DNA hypomethylating agents, which alter how genes function without changing the DNA sequence itself. These medications have shown promise in some blood cancers and are being tested in people with MPNs, particularly those whose disease is progressing or not responding well to standard treatments.^[21]

Eligibility and Participation in Clinical Trials

If you’re interested in participating in a clinical trial, your doctor can help you find studies that might be appropriate for your situation. Each trial has specific eligibility criteria—requirements that determine who can participate. These criteria might include the type of MPN you have, your age, what treatments you’ve already tried, your current blood counts, and your overall health status.

Clinical trials are conducted at specialized medical centers and research hospitals. In the United States, many trials for MPNs are available at major cancer centers. European countries also host numerous studies, and some international trials enroll patients from multiple countries. Your doctor can search clinical trial databases to find studies that are recruiting participants and match your specific needs.^[2]

Participating in a clinical trial offers several potential benefits. You may gain access to promising new treatments before they’re widely available, receive close monitoring from experts in MPNs, and contribute to research that could help future patients. However, there are also considerations to keep in mind: new treatments may not work better than existing ones, they may have unexpected side effects, and trials often require more frequent visits and tests than standard care.

International Research Efforts

Research into better MPN treatments is a global effort. Scientists and doctors from around the world collaborate to understand these diseases better and develop new therapies. Organizations like the MPN Research Foundation support research projects and help connect researchers, while patient registries collect information from thousands of people with MPNs to help identify patterns and improve care.^[18]

This international collaboration means that advances made in one country can quickly benefit patients everywhere. It also increases the diversity of people enrolled in studies, which helps ensure that new treatments work well for people of different backgrounds, ages, and disease characteristics.

Most common treatment methods

• Blood cell reduction procedures
  • Venesection (phlebotomy) for polycythemia vera—a simple procedure where blood is removed to reduce red blood cell counts and prevent blood from becoming too thick
• Medications to control blood counts
  • Hydroxyurea—slows down rapid blood cell production in the bone marrow, helping bring elevated counts toward normal levels
  • Anagrelide—specifically lowers platelet counts in people with essential thrombocythemia by interfering with platelet-producing cells
  • Interferon therapy—uses synthetic versions of natural immune substances to slow abnormal blood cell growth and may help control genetic mutations
• Clot prevention therapy
  • Low-dose aspirin—makes platelets less sticky, reducing the risk of dangerous blood clots that can cause heart attacks or strokes
  • Anticoagulant medications—in some cases, stronger blood thinners may be needed for people with history of blood clots
• Targeted therapy
  • Tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia—including imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, which block the abnormal BCR-ABL1 protein
  • JAK2 inhibitors like ruxolitinib—block abnormal signaling that drives excessive blood cell production, particularly helpful for myelofibrosis
• Stem cell transplantation
  • Bone marrow or stem cell transplant from a donor—the only potentially curative treatment, typically reserved for some people with myelofibrosis or those whose disease has transformed into acute leukemia
  • This intensive treatment carries significant risks and is not suitable for everyone, particularly older patients or those with other health conditions
• Supportive care medications
  • Erythropoiesis-stimulating agents (ESAs)—help treat anemia in some MPN patients by stimulating red blood cell production
  • Prednisone—a steroid medication sometimes used to manage specific symptoms or complications
• Experimental treatments in clinical trials
  • Newer JAK inhibitors with potentially fewer side effects
  • DNA hypomethylating agents that alter gene function
  • Combination therapies using multiple drugs together
  • Treatments targeting molecular pathways beyond JAK2
  • Drugs to reduce bone marrow scarring in myelofibrosis